OncoMatch/Clinical Trials/NCT04644016

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

Is NCT04644016 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for aml.

Phase 2RecruitingMemorial Sloan Kettering Cancer CenterNCT04644016Data as of May 2026

Treatment: Clofarabine · Fludarabine · Busulfan · Cyclosporine-A · Mycophenolate Mofetil · Cord Blood Graft — This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia

Myelodysplastic Syndrome

Myeloproliferative Neoplasm

Non-Hodgkin Lymphoma

Prior therapy

Cannot have received: autologous stem cell transplant

Exception: allowed if > 6 months prior

Autologous stem cell transplant within the preceding 6 months

Cannot have received: allogeneic stem cell transplant

Any prior allogeneic stem cell transplant

Lab requirements

Blood counts

MDS/MPD patients must have less than 10% bone marrow myeloblasts and ANC ≥ 0.2 (growth factor supported if necessary) at transplant work-up

Kidney function

serum creatinine ≤ 1.5x normal for age. If serum creatinine is outside the normal range, then CrCl > 50 mL/min/1.73m2 (calculated or estimated) or GFR (mL/min/1.72m2) >30% of predicted normal for age

Liver function

Bilirubin ≤ 1.5 mg/dL (unless benign congenital hyperbilirubinemia); ALT ≤ 3 x upper limit of normal

Cardiac function

Left ventricular ejection fraction ≥ 50%

Bilirubin ≤ 1.5 mg/dL (unless benign congenital hyperbilirubinemia). ALT ≤ 3 x upper limit of normal. Pulmonary function (spirometry and corrected DLCO) ≥ 50% predicted (corrected for hemoglobin). Left ventricular ejection fraction ≥ 50%. Age-adjusted Hematopoietic Cell Transplantation-Comorbidity Index (aaHCT-CI) ≤ 7. Renal: serum creatinine ≤ 1.5x normal for age. If serum creatinine is outside the normal range, then CrCl > 50 mL/min/1.73m2 (calculated or estimated) or GFR (mL/min/1.72m2) >30% of predicted normal for age.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Memorial Sloan Kettering Cancer Center · New York, New York

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify